Author

Adelyn Bolithon

Observed name: Bolithon, Adelyn

Institution: UNSW Sydney

Observed institutions: The University of Queensland, UNSW Sydney

ORCID: 0000-0003-1914-6125

Observed ORCID: 0000-0003-1914-6125

OpenAlex ID: A5025511650

CCNE1 and survival of patients with tubo‐ovarian high‐grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study

2022 · Eun‐Young Kang, Ashley Weir, et al. · Cancer · 51

Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes

2022 · Nicola S. Meagher, Kylie L. Gorringe, et al. · Clinical Cancer Research · 25

MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma

2021 · Eun Young Kang, Joshua Millstein, et al. · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · 20

Immunological and molecular features of the tumor microenvironment of long-term survivors of ovarian cancer

2024 · Brad H. Nelson, Phineas Hamilton, et al. · Journal of Clinical Investigation · 19

Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma

2024 · Flurina A.M. Saner, Kazuaki Takahashi, et al. · Clinical Cancer Research · 16

Sgk-1 is a Positive Regulator of Constitutive Albumin Uptake in Renal Proximal Tubule Cells

2012 · Deanne H. Hryciw, Wade A. Kruger, et al. · Cellular Physiology and Biochemistry · 10

Concurrent RB1 loss and BRCA -deficiency predicts enhanced immunological response and long-term survival in tubo-ovarian high-grade serous carcinoma

2023 · Flurina A. M. Saner, Kazuaki Takahashi, et al. · medRxiv · 6

Ovarian cancer risk and survival according to tumor sex hormone receptor expression: An ovarian Cancer association consortium and ovarian tumor tissue analysis consortium pooled analysis

2025 · Zhuxuan Fu, Lauren Borho, et al. · Gynecologic Oncology · 3

Clinicopathologic and molecular predictors of survival in BRCA-deficient tubo-ovarian high-grade serous carcinoma

2026 · Tibor A. Zwimpfer, Sian Fereday, et al. · Nature Communications · 2

Supplementary Figures S1-S13 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes

2025 · Nicola S. Meagher, Kylie L. Gorringe, et al.

Table 2 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes

2025 · Nicola S. Meagher, Kylie L. Gorringe, et al.

Figure 3 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes

2025 · Nicola S. Meagher, Kylie L. Gorringe, et al.

Figure 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes

2025 · Nicola S. Meagher, Kylie L. Gorringe, et al.

Table 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes

2025 · Nicola S. Meagher, Kylie L. Gorringe, et al.

Supplementary Tables S1-S11 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes

2025 · Nicola S. Meagher, Kylie L. Gorringe, et al.

Supplementary Methods 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes

2025 · Nicola S. Meagher, Kylie L. Gorringe, et al.

Figure 2 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes

2025 · Nicola S. Meagher, Kylie L. Gorringe, et al.

Table 3 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes

2025 · Nicola S. Meagher, Kylie L. Gorringe, et al.

Beyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA-deficient tubo-ovarian high-grade serous carcinoma

2025 · Dale Garsed, Tibor Zwimpfer, et al. · Research Square

Beyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA -deficient tubo-ovarian high-grade serous carcinoma

2025 · Tibor A. Zwimpfer, Sian Fereday, et al. · medRxiv

Figure 1 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma

2024 · Flurina A.M. Saner, Kazuaki Takahashi, et al.

Supplementary Figure S10 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma

2024 · Flurina A.M. Saner, Kazuaki Takahashi, et al.

Supplementary Figure S5 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma

2024 · Flurina A.M. Saner, Kazuaki Takahashi, et al.

Data from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma

2024 · Flurina A.M. Saner, Kazuaki Takahashi, et al.

Supplementary Table S2 from Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma

2024 · Flurina A.M. Saner, Kazuaki Takahashi, et al.

Works count: 106

Citation count: 152

H-index: 6

I10-index: 6